Cardiac amyloidosis continues to get more and more attention at cardiology meetings. At Heart Failure 2026 in Spain, it was the topic of multiple studies, including one on the benefits of acoramidis.
Up to 30% of U.S. patients carry genetic variations that reduce the effectiveness of clopidogrel, an antiplatelet medication sold under the brand name Plavix.
This new catheter-based device for lymphatic drainage showed early potential to be an effective treatment option for acute decompensated heart failure.
The REVEAL study has been assessing the sensitivity and specificity of iodine 124 evuzamitide (I 124 evuzamitide), a PET agent capable of visualizing signs of cardiac amyloidosis on imaging.
Researchers combined data from three well-known clinical trials—NOTION, Evolut Low Risk and PARTNER 3—and evaluated thousands of low-risk patients who presented with severe aortic stenosis.
In 2023, the Society of Abdominal Radiology released its consensus statement regarding follow-up imaging of patients who have had their cancer surgically resected.
Researchers tracked patients undergoing elective cardiac surgery at a high-volume medical center, treating 50% of the selected cohort with above-average oxygen levels.
Patients have typically been told to take aspirin and an oral anticoagulant following treatment to help combat the risk of blood clots. Now, they can skip the aspirin altogether.
![A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]](/sites/default/files/styles/top_stories/public/2024-09/istock-1209664264.jpg.webp?itok=gQInU1vO)
![Treating atrial functional mitral regurgitation (AFMR) with surgery may be more beneficial than medical therapy alone, according to new data published in JAMA Network Open.[1]](/sites/default/files/styles/240x220/public/2024-08/screenshot_2024-08-22_at_3.41.23_pm.png.webp?itok=yzxZh3wV)
